摘要
非酒精性脂肪性肝病(NAFLD)是以弥漫性肝细胞大泡性脂肪变性为主要特征,且患者并无过量饮酒史的临床综合征,其基础治疗目前仍以饮食控制及运动为主;合并高脂血症的NAFLD患者,改变生活方式和(或)接受降糖或减轻体重药物治疗3～6月以上仍有混合性高脂血症或高脂血症合并2个以上心血管危险因素者,加用他汀类、贝特类或普罗布考等调脂药物,可延缓患者动脉粥样硬化进程,减少心脑血管事件的发生。本文简要综述调脂药物在NAFLD中的应用。
Nonalcoholic fatty liver disease （NAFLD） is a syndrome characterized by diffuse macrovesicular steatosis without excessive use of alcohol. Presently the major treatments of NAFLD are diet-control and exercise. However, for the patients with NAFLD complicating hyperlipidemia, lipid-regulating drugs such as fibrates, statins or probucol should be considered if mixed hyperlipidemia or hyperlipidemia with two or more risk factors still exists through lifestyle changes and （or） the application of weight-reducing or hypoglycemic drugs for more than 3-6 months. This review summarizes the application of lipid-regulating drugs in NAFLD.
出处
《世界临床药物》
CAS
2010年第9期530-533,共4页
World Clinical Drug
关键词
脂肪性肝病
非酒精性
调脂药物
fatty liver disease
nonalcoholic
lipid-regulating drugs
